EX-10.1





 Exhibit 10.1 

FORM OF INVESTOR SUBSCRIPTION AGREEMENT 

Erytech Pharma S.A. 
 Bâtiment Adénine 

60 Avenue Rockefeller 
 69008 Lyon 

France 
 The undersigned (the “Investor”) hereby
confirms its agreement with you as follows: 
  

	1.	 This Subscription Agreement (the “Agreement”) is made as of the date set forth below between
Erytech Pharma S.A., a societé anonyme organized under the laws of France, with a share capital of €2,794,012.10 and a registered office at Bâtiment Adénine, 60 Avenue Rockefeller, 69008 Lyon France, registered with
the Register of Commerce and Companies (Registre du commerce et des sociétés) of Lyon under the number 479 560 013 (the “Company”), and the Investor. 



 

	2.	 The Investor wishes to purchase and the Company wishes to issue, upon the terms and conditions stated in this
Agreement (the “Offering”), without preferential subscription rights to specified categories of investors up to 769,608 units of shares with warrants attached (Actions à bons de souscription
d’actions or ABSA) (the “Units”), each consisting of (i) four ordinary shares, par value €0.10 per share (each, a “Share”) and (ii) three warrants, each warrant to
purchase one Share (each, a “Warrant”), whose Terms and Conditions (the “Terms and Conditions of the Warrants”) are attached hereto as Exhibit A (as exercised, collectively the “Warrant
Shares”), for a subscription price of $10.20 per Unit (the “Subscription Price”), pursuant to the 18th resolution of the combined general meeting of the shareholders of the Company held on June 25, 2021 (the
“18th Resolution”). The issuance of the Shares will result in an immediate capital increase of €6,957,256.32 (divided into a nominal amount of € 307,843.20 and a total issuance premium of €6,649,413.12 and
corresponding to a nominal value of ten cents (€0.10) plus an issuance premium of €2.16 per Share issued). Immediately upon creation, each Share within a Unit will be transferred to The Bank of New York Mellon (the
“Depositary”) and the Depositary will issue one American Depositary Share (“ADS”) instead of such Share to the Investor purchasing such Unit. 



 

	3.	 The Shares, including as represented by the ADSs, the Warrants and the Warrant Shares collectively are referred
to herein as the “Securities.” 


  

	4.	 The Securities will be issued pursuant to an effective registration statement under the U.S. Securities Act of
1933, as amended (the “Securities Act”). 


  

	5.	 In connection with the offering and sale of the Securities, the Company has entered into a placement agent
agreement dated December 13, 2021 (the “Placement Agent Agreement”) with H.C. Wainwright & Co., LLC (the “Placement Agent”). 



 

	6.	 The Company and the Investor agree that the Investor will subscribe from the Company and the Company will issue
to the Investor, who meets the categories defined in the 18th Resolution, namely (i) natural and legal persons, including companies, trusts or investment funds, organized under French or foreign law, that regularly invest in the pharmaceutical,
biotechnological or medical technology sector and/or (ii) companies, institutions or entities of any type, French or foreign, that exercise a significant part of their business in the pharmaceutical, cosmetic, chemical or medical devices and/or
technologies or research in these sectors, the number of Units set forth below for the aggregate subscription price set forth below. The Units shall be subscribed for pursuant to, and the manner of settlement shall be as set forth in, the Terms and
Conditions for Subscription of Units attached hereto as Annex I and incorporated herein by this reference as if fully set forth herein. The Investor expressly acknowledges and agrees that all representations, warranties, covenants and
agreements made or given by the Investor to the 



  
 1 














	 	
Company herein, and specifically as made or given in the Terms and Conditions for Subscription of Units attached hereto as Annex I, are also irrevocably made and given for the benefit of
the Placement Agent (as defined in Annex I hereto) and that the Placement Agent is entitled to rely on the same in connection with the placement of the Units. 


 

	7.	 The Company and the Investor agree that the Investor may, on an annual basis, request information related to
the Company’s status for United States federal income tax purposes as a “passive foreign investment company” and information required for IRS form 5471 status and the Company will use its commercially reasonable efforts to provide any
information the Company has in its possession or can obtain without significant burden that the Investor is required to have under United States tax law for such purpose. 



 

	8.	 Restriction on Sales of Securities. During the period beginning on the date hereof and continuing
through the close of trading on the date that is the 75th day immediately following the Closing Date (as defined in Annex I hereto) (the
“Lock-Up Period”), the Company will not, without the prior written consent of the Investor, which consent may be withheld in the Investor’s sole discretion, directly or indirectly:
(i) issue, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of any ADSs, Shares or
other share capital or any securities convertible into or exercisable or exchangeable for ADSs, Shares or other share capital, (ii) file or cause the filing of any registration statement under the Securities Act with respect to any ADSs, Shares
or other share capital or any securities convertible into or exercisable or exchangeable for any ADSs, Shares or other share capital (other than any Rule 462(b) Registration Statement filed to register Securities to be sold pursuant to the documents
executed and delivered by the Company and the Investor in connection with the Offering (the “Transaction Documents”)), or (iii) enter into any swap or other agreement, arrangement, hedge or transaction that transfers to another, in
whole or in part, directly or indirectly, any of the economic consequences of ownership of any ADSs, Shares or other share capital or any securities convertible into or exercisable or exchangeable for any ADSs, Shares or other share capital, whether
any transaction described in clause (i) or (iii) above is to be settled by delivery of ADSs, Shares, other share capital, other securities, in cash or otherwise, or publicly announce any intention to do any of the foregoing. Notwithstanding the
provisions set forth in this Section 8), the Company may, without the prior written consent of the Investor, (A) issue the Securities to the Investors pursuant to the Transaction Documents; (B) issue ADSs or ordinary shares, and
options or warrants (including founder’s share warrants (BSPCE) or share warrants (BSA)) to purchase ADSs or ordinary shares, pursuant to stock option plans, stock purchase or other equity incentive plans described in the Prospectus, as those
plans are in effect on the date of this Agreement; (C) issue ADSs or ordinary shares upon the exercise of stock options or warrants issued under stock option or other equity incentive plans referred to in clause (B) above, as those plans
are in effect on the date of this Agreement, or upon the exercise of warrants or convertible securities or notes warrants (BEOCABSA) (including those issued in the context of the convertible bond financing entered into with Alpha Blue Ocean on
June 24, 2020) outstanding on the date of this Agreement, as those warrants and convertible securities are in effect on the date of this Agreement; provided that such securities have not been amended since the date of this Agreement to increase
the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities; (D) file a
registration statement on Form S-8 to register ADSs or ordinary shares issuable pursuant to the terms of stock option or other equity incentive plans referred to in clause (B) above, and (E) issue
ADSs or ordinary shares in connection with any strategic partnering transitions, including any joint venture, commercial or collaborative relationship or the acquisition or license by the Company of the securities, business, property or other assets
of another person or entity or pursuant to any employee benefit plan as assumed by the Company in connection with any such acquisition, provided that in the case of this clause (E) the aggregate number of ADSs or ordinary shares issued in all
such transactions does not exceed 10% of either the outstanding ADSs or ordinary 



  
 2 














	 	
shares, provided that such securities are issued as “restricted securities” (as defined in Rule 144 under the Securities Act) and carry no registration rights that require or permit the
filing of any registration statement in connection therewith during the Lock-Up Period, and provided further that the Investor’s receive a signed lock-up agreement
for the balance of the Lock-Up Period with respect to any such ADSs or ordinary shares so issued. 

  

	9.	 The Investor represents and warrants that, except as set forth below, it has had no position, office or other
material relationship (including, but not limited to, a commercial, industrial, banking, consulting or accounting relationship) within the past three years with the Company or any of its affiliates. 



Exceptions1: 
  

	
	  

	1(If no exceptions, write “none.” If left blank, response will be deemed to be “none.”)

 The Investor agrees that prior to the Closing Date (as defined in Annex I hereto) it will complete the following
information and deliver it to the Company: 
 Number of Units Subscribed (please hand-write the following below: “good for commitment to subscribe for
[insert number of Units subscribed in letters] [(insert number of Units subscribed in numbers)] Units.”)1: 769,608 

 

	
	      

	      

	      

	 Subscription Price Per Unit: $10.20

Aggregate Subscription Price: $7,850,001.60


 The Aggregate Subscription Price will be paid in U.S. dollars to the following account of the Placement Agent: 

Agent: [●] 
 Agent BIC Code:
[●] 
 Beneficiary: [●] 

A/C [●] 
 IBAN: [●]

 for subsequent transfer to the account opened in the books of Société Générale Securities Services for the Offering as set
forth in Section 3.3 of Annex I. 
  

	1 	 French law requirement: The Investor shall include a handwritten note after signature block “valuable for
[number of Units subscribed in letters] (number of Units subscribed in numbers) Units.” 



  
 3 













 Please confirm that the foregoing correctly sets forth the agreement between the Company and the Investor by
signing in the space provided below for that purpose. 
 Dated as of: December 14, 2021 

Armistice Capital Master Fund Ltd. 
 INVESTOR 

 

			
	By:	 	 /s/ Steven Boyd

	Print Name:	 	 Steven Boyd

	Title:	 	 CIO of Armistice Capital, LLC, the Investment Manager

	Address:	 	c/o Armistice Capital, LLC
		 	510 Madison Avenue, 7th Floor
		 	 New York, NY 10022


 [Please insert the following in case of execution of the Agreement by a management company on behalf of investment
funds 
 Name(s) of the investment funds represented by the Investor and number of Units subscribed by each of them: 

 

							
	 Armistice Capital Master Fund Ltd.
	  	for	  	 769,608
	  	Units
				
	  
	  	for	  	  
	  	Units
				
	  
	  	for	  	  
	  	Units
				
	  
	  	for	  	  
	  	Units]

  

			
	Agreed and Accepted
	this 14th day of December, 2021:
	
	ERYTECH PHARMA S.A.
		
	By:	 	 /s/ Gil Beyen

	Name:	 	 Gil Beyen

	Title:	 	 Chief Executive Officer


 [SUBSCRIPTION AGREEMENT SIGNATURE PAGE] 












 ANNEX I 

TERMS AND CONDITIONS FOR SUBSCRIPTION OF UNITS 
  

	1.	 Authorization and Issuance of the Units 



Subject to the terms and conditions of this Agreement, the Company has authorized the issuance of the Units, each consisting of four
(4) Shares and three (3) Warrants. Each Warrant shall entitle the Investor to subscribe for one (1) new Share of the Company at a subscription price of €2.26 per Share (including an issuance premium of €2.16). Immediately
upon creation, each Share within a Unit will be transferred to the Depositary and the Depositary will issue one ADS representing each such Share to the Investor purchasing such Unit. 

The Company will cause the Shares and the Warrant Shares to be approved for admission to trading on the regulated market of Euronext Paris on
the same date as the Closing Date (as defined in Section 3.1). 
 The Company will cause the Warrants to be
admitted to the operations of Euroclear France SA on the Closing Date. 
  

	2.	 Agreement to Issue and Subscribe for the Units; Placement Agent 



 

	2.1	 The Units are being or will be offered pursuant to an effective registration statement under the U.S.
Securities Act of 1933, as amended and, as the case may be, in the European Union, pursuant to Article 1, paragraph 4 a) of Regulation (EU) 2017/1129 of the European Parliament and of the Council dated 14 June 2017, as amended (the
“Prospectus Regulation”). 


  

	2.2	 On the Closing Date (as defined in Section 3.1), the Company will issue to the
Investor, and the Investor will subscribe for, upon the terms and conditions set forth herein, the number of Units set forth on the penultimate page of the Agreement to which these Terms and Conditions for Subscription of Units are attached as
Annex I (the “Signature Page”) for the aggregate subscription price set forth on the Signature Page. 


  

	2.3	 The Investor acknowledges that the Company intends to pay H.C. Wainwright & Co., LLC
(“HCW” or the “Placement Agent”) certain placement fees and expenses in respect of the sale of Units to the Investor. 


  

	2.4	 The Company has entered into a placement agent agreement with the Placement Agent that contains certain
customary representations, warranties, covenants and agreements of the Company for the benefit of the Placement Agent alone. 


  

	2.5	 The Placement Agent shall be the third-party beneficiary of the representations, warranties and covenants of
the Investor in Section 4 below. 


  

	3.	 Closings and Delivery of the Units and Funds  



 

	3.1	 Closing 



The time and date of closing of the Offering (the “Closing”) shall be at 04:00 p.m. (CET), on or before December 20, 2021
(the “Closing Date”) as agreed by the Company and the Placement Agent. By executing this Agreement, the Investor consents and agrees to any later date and time agreed to by the Company and the Placement Agent. 

The Company has designated Société Générale Securities Services as “banque centralisatrice” and
“dépositaire” (the “Centralizing Bank”) to receive the subscriptions and payment for the subscriptions of the Units in accordance with Section 3.3 below. 

  
 1 














					
	3.2	  	(a)	  	Conditions to the Company’s Obligation 

 The Company’s obligation to issue the Units to each Investor at the Closing is subject to the
satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion by providing each Investor
with prior written notice thereof: 
 (i) Such Investor shall have executed and delivered to HCW this Agreement. 

(ii) Such Investor shall have delivered to the Company, through HCW, the subscription price for the Units being subscribed for hereunder as set
forth on the Signature Page by the Investor by wire transfer of immediately available funds pursuant to the wire instructions. 
 (iii) The
accuracy of the representations and warranties made by the Investor shall be true and correct in all material respects and as of the date when made and as of the Closing Date as though made at that time (except for representations and warranties
that speak as of a specific date, which shall be true and correct as of such specified date), and such Investor shall have performed, satisfied and complied in all material respects with the undertakings of the Investor required by this Agreement to
be fulfilled prior to the Closing Date. 
  

	 	(b)	 Conditions to the Investor’s Obligation 



The Investor’s obligations are expressly not conditioned on the subscription by any or all of the Investors of the Units that they have
agreed to subscribe from the Company. 
  

	3.3	 Delivery of Funds 



 

	(a)	 Prior to the Closing Date, the Investor shall wire transfer the aggregate subscription price to the account of
HCW or its clearing agent and shall notify the Company and HCW of (i) the account from which the aggregate subscription price will be wired to the account of HCW or its clearing agent for subsequent transfer to the account opened in the books
of Société Générale Securities Services, (ii) the account to be credited by the Depositary with the ADSs to be issued instead of the Shares being purchased by such Investor as part of the Units, and (iii) the
account opened in the name of the Investor and to which the Warrants will be credited by the Centralizing Bank. Such notification shall be effected using the Form of Notice set forth in Exhibit B hereto. 



The account of HCW or clearing agent to which the aggregate subscription price shall be wired in U.S. dollars by the Investor is set forth in
the Signature Page. 
  

	(b)	 By executing this Agreement, the Investor irrevocably instructs HCW or its clearing agent to deliver, and the
Centralizing Bank to accept delivery of, the subscription monies from their respective settlement accounts to the augmentation de capital bank account opened at the Centralizing Bank in its book in the name of the Company upon notice from HCW
or the clearing agent to the Centralizing Bank that the conditions to the closing of the Offering have been satisfied or waived. 


  

	(c)	 If the conditions to the closing of the Offering have not been satisfied or waived, then the Company undertakes
to return any amount wired by the Placement Agent or its clearing agent on behalf of the Investor to the account opened in the books of the Centralizing Bank to the account specified by the Investor pursuant to
Section 3.3(a) above as soon as possible, and in no event later than two (2) business days after the day on which the Company or the Placement Agent shall have determined that such closing conditions are definitively
not satisfied or definitively cannot be waived. 



  
 2 














	(d)	 Prior to the Closing Date, the Investor shall have furnished to the Placement Agent and the Company such other
further information, certificates and documents as such Placement Agent or the Company may reasonably request. 


  

	3.4	 Delivery of Units 



On the Closing Date, subject to and upon receipt of the aggregate subscription amount of the Offering on the Closing Date and the issuance of
the depositary certificate (certificat du dépositaire des fonds) required by Article L. 225-146 of the French Commercial Code by the Centralizing Bank, all of the Shares and
Warrants corresponding to the subscribed Units will be created and registered no later than on the Closing Date. All Shares shall be delivered by the Centralizing Bank to the Depositary to the account specified by the Investor pursuant to
Section 3.3(a) above and all Warrants shall be delivered by the Centralizing Bank to the Investor to the account specified by the Investor pursuant to Section 3.3(a). 

 

	3.5	 American Depositary Shares 



The Investor is hereby notified that if the Investor wants to convert the Warrant Shares into ADSs, then the Company will use best efforts to
facilitate such conversion with the Investor and the Depositary for the ADSs. The Company shall pay all Depositary fees in relation to the foregoing (including, without limitation, any fees required for
same-day processing of any instruction letter delivered by the Company or its agent and any exercise notice delivered by an Investor). 
  


	4.	 Representations, Warranties and Covenants of the Investor 



 

	4.1	 The Investor represents and warrants to, and covenants with, the Company that: 



 

	 	(a)	 The Investor acknowledges that there may be certain consequences under U.S. and other tax laws resulting from
an investment in the Units and the Warrant Shares and will make such investigations and consult such tax and other advisors with respect thereto as it deems appropriate and prior to purchasing the Units and the Warrant Shares, it will have satisfied
itself, without limitation, concerning the effects of U.S. federal, state and local income tax laws and foreign tax laws concerning its investment in the Units and the Warrant Shares. 



 

	4.2	 Any Investor that is not located in the United States further represents and warrants to, and covenants with,
the Company that the Investor is a qualified investor as defined in Article 2(e) of the Prospectus Regulation. 


  

	4.3	 The Investor further represents and warrants to, and covenants with, the Company that: 



 

	 	(a)	 The Investor is a (i) natural and legal person, including company, trust or investment fund, organized
under French or foreign law, that regularly invest in the pharmaceutical, biotechnological or medical technology sector and/or (ii) company, institution or entity of any type, French or foreign, that exercise a significant part of its business
in the pharmaceutical, cosmetic, chemical or medical devices and/or technologies or research in these sectors; provided that, if the Investor is acting on behalf of investment funds or other legal entities managed or advised by it such
representation shall also apply to each such funds or legal entities and the Investor shall further ensure compliance thereof by each such funds or entities in connection with the initial distribution of the Units. 



 

	4.4	 The Investor understands that the Placement Agent has acted solely as the agent of the Company in this
placement of the Units and not to the Investor, and that each of the Placement Agent and its representatives make no representation or warranty with regard to the merits of the Offering or as to the completeness or accuracy of any information or
materials such Investor may have received in connection therewith. The Investor acknowledges that it has not relied on any 



  
 3 














	 	
information, representations or advice furnished by or on behalf of the Placement Agent or any affiliate thereof or any representative of the Placement Agent or its affiliates in making a
decision to purchase the Units. 

  

	4.5	 The Investor acknowledges, represents and agrees that no action has been or will be taken in any jurisdiction
other than the United States and the Republic of France, which would permit a public offering of the Units or the Warrant Shares, or possession or distribution of offering materials in connection with the issuance of the Units or the Warrant Shares
in any jurisdiction where action for that purpose is required. 


  

	4.6	 The Investor further represents and warrants to, and covenants with, the Company that (a) the Investor has
full right, power, authority and capacity to enter into this Agreement (including the Terms and Conditions of the Warrants) and to consummate the transactions contemplated hereby and has taken all necessary action to authorize the execution,
delivery and performance of this Agreement (including the Terms and Conditions of the Warrants), and (b) this Agreement and the Terms and Conditions of the Warrants constitute a valid and binding obligation of the Investor enforceable against
the Investor in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except
as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). 



 

	4.7	 All of the Investor’s information on the Signature Page hereto may be used in connection with the
admission to trading of the Shares on Euronext Paris and the information thereon is true and correct as of the date hereof and will be true and correct as of the Closing Date. 



 

	4.8	 The Investor represents and warrants that the proceeds funds will not be derived from sources prohibited under
any sanctions programs administered by the U.S. Treasury Department’s Office of Foreign Assets Control or any or any applicable prohibited party list maintained by any U.S. government agency, French government agency, the European Union, or Her
Majesty’s Treasury. 


  

	5.	 Survival of Representations, Warranties and Agreements 



Notwithstanding any investigation made by any party to this Agreement or by the Placement Agent, all covenants, agreements, representations and
warranties made by the Investor herein will survive the execution of this Agreement, the delivery to the Investor of the Units being subscribed and the payment therefor. 
  

	6.	 Notices 



All notices, requests, consents and other communications hereunder will be in writing, will be mailed by International Federal Express or
delivered by facsimile, and will be deemed given (i) if delivered by International Federal Express, two (2) business days after so mailed or (ii) if delivered by facsimile, upon electronic confirmation of receipt and will be delivered
as addressed as follows: 
  

	 	(a)	 if to the Company, to: 



Erytech Pharma S.A. 

Bâtiment Adénine 
 60
Avenue Rockefeller 
 69008 Lyon 

France 
 Facsimile: +33 (0)4 78 75
56 29 
 Attention: General Counsel 

  
 4 













 with a copy (for informational purposes only) to: 

Cooley LLP 
 500 Boylston
Street 
 14th Floor 
 Boston,
Massachusetts 02116 
 Facsimile: +1 617 937 2400 

Attention: Marc Recht 
 H.C.
Wainwright & Co., LLC 
 430 Park Avenue, 3rd Floor 

New York, New York 10022 

Facsimile: + 212 356 0500 

Attention: Mark W. Viklund 
  

	 	(b)	 if to the Investor, at its address set forth in the Agreement, or at such other address or addresses as may
have been furnished to the Company in writing. 


  

	7.	 Changes 



This Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company and the Investor. 

 

	8.	 Headings 



The headings of the various sections of this Agreement have been inserted for convenience of reference only and will not be deemed to be part
of this Agreement. 
  

	9.	 Severability 



In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and
enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby. 
  

	10.	 Governing Law and Jurisdiction 



This Agreement, and any non-contractual obligations arising out of this Agreement, shall be governed
by, and construed in accordance with the laws of France. Any dispute or suit relating to the interpretation, validity and performance of this Agreement, or arising out of or as a consequence hereof, shall be subject to the exclusive jurisdiction of
the Tribunal de Commerce of Paris. 
  

	11.	 Execution of Agreement; Effectiveness 



This Agreement has been executed in two originals, one for each party. This Agreement will become effective upon execution and delivery by the
Company and the Investor. 
  

	12.	 Termination 



In the event that the Closing shall not have occurred with respect to an Investor on or before ten (10) Business Days from the date hereof
due to the Company’s or such Investor’s failure to satisfy the conditions set forth herein (and the nonbreaching party’s failure to waive such unsatisfied condition(s)), the nonbreaching party shall have the option to terminate this
Agreement with respect to such breaching party at the close of business on such date without liability of any party to any other party. 

  
 5 














	14.	 Exculpation of Placement Agent 



Each party hereto agrees for the express benefit of the Placement Agent, its affiliates and representatives that: 

 

	 	(a)	 Neither the Placement Agent nor any of its affiliates or representatives (1) have any duties or
obligations under this Agreement other than those specifically set forth herein; (2) shall be liable for any improper payment made in accordance with this Agreement and the information provided herein by the Company; (3) make any
representation or warranty, or have any responsibilities as to the validity, accuracy, value or genuineness of any information, certificates or documentation delivered by or on behalf of the Company pursuant to this Agreement; or (4) shall be
liable for anything which any of them may do or refrain from doing in connection with this Agreement, except for such party’s own gross negligence, willful misconduct or bad faith. 



 
  

	 	(b)	 The Placement Agent and its affiliates and representatives shall be entitled to rely on, and shall be protected
in acting upon, any certificate, instrument, opinion, notice, letter or any other document or security delivered to any of them by or on behalf of the Company. 



  
 6 













 EXHIBITS 
  

			
	Exhibit A	  	Terms and Conditions of the Warrants
	Exhibit B	  	Form of Notice
	Exhibit C	  	Form of Lock-up Agreement













 Exhibit A 

Terms and Conditions of the Warrants 

[See attached] 












 Exhibit B 

Form of Notice 
 Bank account from which the
aggregate Subscription Price will be wired: 
 [●] 

Securities account to which the ADSs representing the Shares will be transferred: 

[●] 
 Securities account to which the Warrants will be
transferred: 
 [●] 
 Aggregate Subscription Price:
$[●] 
 Number of Shares: [●] 
 Account to which
the Warrants will be credited: [●] 












 Exhibit C 

Form of Lock-up Agreement 

[See attached]